Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Shaw

Showing results (601-610 of 742) with videos related to

Pageof 75
Sort By:
ESMO Open|July 19, 2018
Patient-reported outcomes in a phase II, North American study of alectinib in patients with <i>ALK</i>-positive, crizotinib-resistant, non-small cell lung cancerSai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, et al.
The New England Journal of Medicine|November 18, 2020
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung CancerAlice T Shaw, Todd M Bauer, Filippo de Marinis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 15, 2018
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX studyS Gadgeel, S Peters, T Mok, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|June 22, 2019
Acyclic Stereocontrol in the Additions of Nucleophilic Alkenes to α-Chiral N-Sulfonyl IminesLucas C Moore, Anna Lo, Jason S Fell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung CancerJessica J Lin, Elizabeth Kennedy, Lecia V Sequist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2012
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancerA T Shaw, A M Varghese, B J Solomon, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2022
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancerJulien Mazieres, Laura Iadeluca, Alice T Shaw, et al.
Annals of the Rheumatic Diseases|April 5, 2008
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapiesE Keystone, P Emery, C G Peterfy, et al.
Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.
British Journal of Cancer|November 18, 2017
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLCShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
Pageof 75

Showing results (601-610 of 742) with videos related to

Sort By:
Pageof 75
ESMO Open|July 19, 2018
Patient-reported outcomes in a phase II, North American study of alectinib in patients with <i>ALK</i>-positive, crizotinib-resistant, non-small cell lung cancerSai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, et al.
The New England Journal of Medicine|November 18, 2020
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung CancerAlice T Shaw, Todd M Bauer, Filippo de Marinis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 15, 2018
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX studyS Gadgeel, S Peters, T Mok, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|June 22, 2019
Acyclic Stereocontrol in the Additions of Nucleophilic Alkenes to α-Chiral N-Sulfonyl IminesLucas C Moore, Anna Lo, Jason S Fell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung CancerJessica J Lin, Elizabeth Kennedy, Lecia V Sequist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2012
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancerA T Shaw, A M Varghese, B J Solomon, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2022
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancerJulien Mazieres, Laura Iadeluca, Alice T Shaw, et al.
Annals of the Rheumatic Diseases|April 5, 2008
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapiesE Keystone, P Emery, C G Peterfy, et al.
Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.
British Journal of Cancer|November 18, 2017
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLCShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.
Pageof 75